Well-being in Cancer Patients With Neuropathy During COVID-19 Who Participated in Prior Clinical Trials

Overseen By Sarah Prinsloo

Age: Any Age

Sex: Any

Trial Phase: Academic

Sponsor: M.D. Anderson Cancer Center

Disqualifiers: No prior consent

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Approved in 3 Jurisdictions This treatment is already approved in other countries

Compensation: Varies

Number of Visits: 1

274 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

This study investigates the experiences of cancer patients with neuropathy during the COVID-19 pandemic to learn how the COVID-19 pandemic affects their quality of life and clinical outcomes. This study will also explore whether there are differences between patients who received neurofeedback (NFB, a type of therapy that is thought to help normalize brain activity) and those who did not. Learning about quality of life in cancer patients with neuropathy during the COVID-19 pandemic may help guide development of programs and policies to improve chronic pain patient care and outcomes during a major global healthcare crisis.

Who Is on the Research Team?

Sarah Prinsloo

Principal Investigator

M.D. Anderson Cancer Center

Are You a Good Fit for This Trial?

Inclusion Criteria

Must have participated in one of the following protocols: 2015-0399, 2012-0642, or 2010-0675

Has an active email address or can be contacted by MyChart or personal email

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Questionnaire

Participants complete an online questionnaire about their experiences regarding the COVID-19 pandemic, including testing, risks of exposure, and quality of life impacts

15 minutes

1 online session

Follow-up

Participants are monitored for changes in health-related quality of life and COVID-19-specific distress

6 months

What Are the Treatments Tested in This Trial?

Interventions

• Neurofeedback

How Is the Trial Designed?

Group I: Observational (questionnaire, quality of life) Experimental Treatment 2 Interventions

Patients complete an online questionnaire over 15 minutes about their experiences regarding the COVID-19 pandemic including testing, risks of exposure, whether people they know have acquired COVID-19, as well as questions on how the pandemic has impacted their quality of life.

Who Is Running the Clinical Trial?

M.D. Anderson Cancer Center

Lead Sponsor

Trials

3,107

Recruited

1,813,000+

National Cancer Institute (NCI)

Collaborator

Trials

14,080

Recruited

41,180,000+